Pharmaceutical Executive February 2018

February 2018 | Volume 38, Issue 2
Pharmaceutical Executive February 2018
From the Editor
Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders—call it the quest to see "what right looks like?"
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive February 2018 issue in an interactive PDF format.
Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders—most importantly, patients and the wider public.
Lieutenant General (Ret) Rick Lynch, US Army, and Bob Jansen, CEO of Zensights, discuss the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader.
The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.
In this Q&A, Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.
2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead? Peter Young reports.
Low-cost follow-ons and biosimilars please payers but heighten competitive battles with brands.
Julian Upton assembles a few rare slivers of positivity on UK pharma's future.
Special Sponsored Section
By Pharmaceutical Executive Editors
In its ambition to further strengthen the nation’s relationship with the global industry, Brazil holds a valuable, eye-catching asset: the dynamism of its huge pharmaceutical market, the sixth-largest in the world.
lorem ipsum